DPYSL3 and metastatic malignant neoplasm: Of the 100 CRMP4 CpG methylation positive patients, 64 cases (64.0%) were clinically confirmed as metastatic cancer patients, while only one case (0.97%) out of 103 CRMP4 CpG methylation negative patients was clinically diagnosed as a metastatic cancer patient.